Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: The IGCS-COL multicentre, randomised, phase III study

S. De Placido, M. Lopez, C. Carlomagno, G. Paoletti, S. Palazzo, L. Manzione, C. Iannace, G. P. Ianniello, F. De Vita, C. Ficorella, A. Farris, G. Pistillucci, M. Gemini, E. Cortesi, V. Adamo, N. Gebbia, S. Palmeri, C. Gallo, F. Perrone, G. PersicoA. R. Bianco

Research output: Contribution to journalArticle

Abstract

The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2 × 2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival advantage. The hazard ratio (HR) of relapse was 0.89 (95% confidence intervals (CI): 0.73-1.09) for patients receiving FA and 0.99 (95% CI 0.80-1.21) for those receiving LEV; corresponding HRs of death were 1.02 (95% CI: 0.80-1.30) and 0.94 (95% CI 0.73-1.20). Nonhaematological toxicity (all grade vomiting, diarrhoea, mucositis, congiuntivitis, skin, fever and fatigue) was significantly worse with FA, while all other toxicities were similar. In the present trial, there was no evidence that the addition of FA or LEV significantly prolongs DFS and OAS of radically resected colorectal cancer patients.

Original languageEnglish
Pages (from-to)896-904
Number of pages9
JournalBritish Journal of Cancer
Volume93
Issue number8
DOIs
Publication statusPublished - Oct 17 2005

Fingerprint

Leucovorin
Adjuvant Chemotherapy
Fluorouracil
Colorectal Neoplasms
Confidence Intervals
Mucositis
Rectal Neoplasms
Colonic Neoplasms
Vomiting
Fatigue
Diarrhea
Fever
Recurrence
Skin
Survival
Therapeutics

Keywords

  • 5-fluorouracil modulation
  • Adjuvant chemotherapy
  • Colorectal cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer : The IGCS-COL multicentre, randomised, phase III study. / De Placido, S.; Lopez, M.; Carlomagno, C.; Paoletti, G.; Palazzo, S.; Manzione, L.; Iannace, C.; Ianniello, G. P.; De Vita, F.; Ficorella, C.; Farris, A.; Pistillucci, G.; Gemini, M.; Cortesi, E.; Adamo, V.; Gebbia, N.; Palmeri, S.; Gallo, C.; Perrone, F.; Persico, G.; Bianco, A. R.

In: British Journal of Cancer, Vol. 93, No. 8, 17.10.2005, p. 896-904.

Research output: Contribution to journalArticle

De Placido, S, Lopez, M, Carlomagno, C, Paoletti, G, Palazzo, S, Manzione, L, Iannace, C, Ianniello, GP, De Vita, F, Ficorella, C, Farris, A, Pistillucci, G, Gemini, M, Cortesi, E, Adamo, V, Gebbia, N, Palmeri, S, Gallo, C, Perrone, F, Persico, G & Bianco, AR 2005, 'Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: The IGCS-COL multicentre, randomised, phase III study', British Journal of Cancer, vol. 93, no. 8, pp. 896-904. https://doi.org/10.1038/sj.bjc.6602800
De Placido, S. ; Lopez, M. ; Carlomagno, C. ; Paoletti, G. ; Palazzo, S. ; Manzione, L. ; Iannace, C. ; Ianniello, G. P. ; De Vita, F. ; Ficorella, C. ; Farris, A. ; Pistillucci, G. ; Gemini, M. ; Cortesi, E. ; Adamo, V. ; Gebbia, N. ; Palmeri, S. ; Gallo, C. ; Perrone, F. ; Persico, G. ; Bianco, A. R. / Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer : The IGCS-COL multicentre, randomised, phase III study. In: British Journal of Cancer. 2005 ; Vol. 93, No. 8. pp. 896-904.
@article{f82dfd1ced734afba9ac7b956996f2fc,
title = "Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: The IGCS-COL multicentre, randomised, phase III study",
abstract = "The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2 × 2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival advantage. The hazard ratio (HR) of relapse was 0.89 (95{\%} confidence intervals (CI): 0.73-1.09) for patients receiving FA and 0.99 (95{\%} CI 0.80-1.21) for those receiving LEV; corresponding HRs of death were 1.02 (95{\%} CI: 0.80-1.30) and 0.94 (95{\%} CI 0.73-1.20). Nonhaematological toxicity (all grade vomiting, diarrhoea, mucositis, congiuntivitis, skin, fever and fatigue) was significantly worse with FA, while all other toxicities were similar. In the present trial, there was no evidence that the addition of FA or LEV significantly prolongs DFS and OAS of radically resected colorectal cancer patients.",
keywords = "5-fluorouracil modulation, Adjuvant chemotherapy, Colorectal cancer",
author = "{De Placido}, S. and M. Lopez and C. Carlomagno and G. Paoletti and S. Palazzo and L. Manzione and C. Iannace and Ianniello, {G. P.} and {De Vita}, F. and C. Ficorella and A. Farris and G. Pistillucci and M. Gemini and E. Cortesi and V. Adamo and N. Gebbia and S. Palmeri and C. Gallo and F. Perrone and G. Persico and Bianco, {A. R.}",
year = "2005",
month = "10",
day = "17",
doi = "10.1038/sj.bjc.6602800",
language = "English",
volume = "93",
pages = "896--904",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer

T2 - The IGCS-COL multicentre, randomised, phase III study

AU - De Placido, S.

AU - Lopez, M.

AU - Carlomagno, C.

AU - Paoletti, G.

AU - Palazzo, S.

AU - Manzione, L.

AU - Iannace, C.

AU - Ianniello, G. P.

AU - De Vita, F.

AU - Ficorella, C.

AU - Farris, A.

AU - Pistillucci, G.

AU - Gemini, M.

AU - Cortesi, E.

AU - Adamo, V.

AU - Gebbia, N.

AU - Palmeri, S.

AU - Gallo, C.

AU - Perrone, F.

AU - Persico, G.

AU - Bianco, A. R.

PY - 2005/10/17

Y1 - 2005/10/17

N2 - The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2 × 2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival advantage. The hazard ratio (HR) of relapse was 0.89 (95% confidence intervals (CI): 0.73-1.09) for patients receiving FA and 0.99 (95% CI 0.80-1.21) for those receiving LEV; corresponding HRs of death were 1.02 (95% CI: 0.80-1.30) and 0.94 (95% CI 0.73-1.20). Nonhaematological toxicity (all grade vomiting, diarrhoea, mucositis, congiuntivitis, skin, fever and fatigue) was significantly worse with FA, while all other toxicities were similar. In the present trial, there was no evidence that the addition of FA or LEV significantly prolongs DFS and OAS of radically resected colorectal cancer patients.

AB - The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2 × 2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival advantage. The hazard ratio (HR) of relapse was 0.89 (95% confidence intervals (CI): 0.73-1.09) for patients receiving FA and 0.99 (95% CI 0.80-1.21) for those receiving LEV; corresponding HRs of death were 1.02 (95% CI: 0.80-1.30) and 0.94 (95% CI 0.73-1.20). Nonhaematological toxicity (all grade vomiting, diarrhoea, mucositis, congiuntivitis, skin, fever and fatigue) was significantly worse with FA, while all other toxicities were similar. In the present trial, there was no evidence that the addition of FA or LEV significantly prolongs DFS and OAS of radically resected colorectal cancer patients.

KW - 5-fluorouracil modulation

KW - Adjuvant chemotherapy

KW - Colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=27144439057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144439057&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602800

DO - 10.1038/sj.bjc.6602800

M3 - Article

C2 - 16222322

AN - SCOPUS:27144439057

VL - 93

SP - 896

EP - 904

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -